Montana § 50-32-606 Designation Of Patient -- Instruction

Montana Statutes

§ 50-32-606 — Designation Of Patient -- Instruction

Montana § 50-32-606

Title 50HEALTH AND SAFETY

Ch. 32CONTROLLED SUBSTANCES

Part 6Help Save Lives From Overdose Act

This text of Montana § 50-32-606 (Designation Of Patient -- Instruction) is published on Counsel Stack Legal Research, covering Montana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Mont. Code Ann. § 50-32-606 (2026).

Text

50-32-606 . Designation of patient -- instruction.

(1)A prescription issued pursuant to 50-32-604 or 50-32-605 must designate the eligible recipient as the patient, regardless of the eligible recipient's status as an individual, organization, agency, or other entity. Except as provided in 50-32-605 , the prescription must be dispensed by a licensed pharmacy.

(2)A licensed pharmacy or medical practitioner dispensing an opioid antagonist shall provide the patient with basic instruction and information, the content of which must be developed by the department and made publicly available on the department's website, concerning recognition of the signs and symptoms of an opioid-related drug overdose, indications for the administration of an opioid antagonist, administration technique, and the

Free access — add to your briefcase to read the full text and ask questions with AI

50-32-606 . Designation of patient -- instruction. (1) A prescription issued pursuant to 50-32-604 or 50-32-605 must designate the eligible recipient as the patient, regardless of the eligible recipient's status as an individual, organization, agency, or other entity. Except as provided in 50-32-605 , the prescription must be dispensed by a licensed pharmacy.
(2) A licensed pharmacy or medical practitioner dispensing an opioid antagonist shall provide the patient with basic instruction and information, the content of which must be developed by the department and made publicly available on the department's website, concerning recognition of the signs and symptoms of an opioid-related drug overdose, indications for the administration of an opioid antagonist, administration technique, and the need for immediate and long-term followup to the administration of the opioid antagonist, including calling 9-1-1.
(3) An eligible recipient described in 50-32-603 (5)(c) through (5)(i) who distributes an opioid antagonist pursuant to 50-32-607 shall:
(a) fulfill the basic instruction and information requirements set forth in subsection (2); and
(b) develop protocol for:
(i) instructing and training the eligible recipient's employees or other authorized personnel that is consistent with the instruction and information developed by the department under subsection (2); and
(ii) the storage, maintenance, and location of the opioid antagonist.